Cue Biopharma Reports Second Quarter 2026 Financial Results and Recent Business Highlights
Cue Biopharma, a clinical stage biopharmaceutical company focused on immune-mediated diseases, reported significant second quarter 2026 financial results including increased revenues from collaborations, one-time non-cash and transaction-related expenses due to licensing agreements, and a net loss of $153.1 million. The company submitted an Investi…